Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MAHOGANY : A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Follicular Lymphoma,Lymphoma

Trial Overview Read MoreRead more

This study is comparing the effectiveness of different targeted therapy treatments in people with relapsed or refractory follicular lymphoma and marginal zone lymphoma.
 

This trial is treating patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Commercial Sponsor

BeiGene Australia Pty Ltd

Summary

This study is recruiting people with relapsed or refractory Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL), and is testing different treatments depending on which disease you have. People with Follicular Lymphoma will be randomly allocated to either the Experimental or Active Comparator Arms. In the Experimental Arm, people with FL will receive a combination of targeted therapies: zanubrutinib and obinutuzumab. Once they have finished receiving the combination treatment, participants will continue receiving zanubrutinib alone. In the Active Comparator Arm, people with FL will receive targeted therapy (rituximab) plus lenalidomide, which is a drug that modifies the response of the immune system. People with Marginal Zone Lymphoma will be randomly allocated to either an Experimental or Active Comparator Arm. In the Experimental Arm, people with MZL will receive combination targeted therapy (zanubrutinib + rituximab). Once they have finished receiving the combination treatment, participants will continue receiving zanubrutinib alone. In the Active Comparator Arm, people with MZL will receive targeted therapy (rituximab) plus lenalidomide, which is a drug that modifies the response of the immune system.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next